|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 167.34 USD | -0.97% |
|
-3.42% | -25.76% |
| 04-10 | Glenmark Pharmaceuticals Limited Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 Mg | CI |
| 04-09 | Glenmark Pharma Gets US FDA Final Nod for Progesterone Vaginal Inserts | MT |
| Capitalization | 28.09B 23.93B 22.15B 20.85B 38.84B 2,613B 39.64B 260B 102B 1,255B 105B 103B 4,470B | P/E ratio 2026 * |
20.7x | P/E ratio 2027 * | 17.2x |
|---|---|---|---|---|---|
| Enterprise value | 41.09B 35.01B 32.4B 30.5B 56.82B 3,822B 57.98B 380B 149B 1,835B 154B 151B 6,539B | EV / Sales 2026 * |
2.38x | EV / Sales 2027 * | 2.21x |
| Free-Float |
67.55% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Iqvia Holdings Inc.
| 1 day | -0.97% | ||
| 1 week | -3.42% | ||
| Current month | -1.88% | ||
| 1 month | -2.47% | ||
| 3 months | -30.97% | ||
| 6 months | -15.56% | ||
| Current year | -25.76% |
| 1 week | 163.59 |  | 178.56 |
| 1 month | 162.36 | | 178.56 |
| Current year | 156.66 | | 247.04 |
| 1 year | 134.64 | | 247.04 |
| 3 years | 134.64 | | 261.73 |
| 5 years | 134.64 | | 285.61 |
| 10 years | 61.21 | | 285.61 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 65 | 03/10/2016 |
Michael Fedock
DFI | Director of Finance/CFO | 50 | 28/02/2026 |
Jeffrey Spaeder
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
John Leonard
BRD | Director/Board Member | 68 | 05/02/2015 |
Ari Bousbib
CHM | Chairman | 65 | 03/10/2016 |
Todd Sisitsky
BRD | Director/Board Member | 54 | 01/01/2016 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -.--% | 2.92% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.97% | -3.42% | +14.97% | -16.20% | 28.09B | |
| +1.74% | +0.55% | -1.64% | -9.59% | 45.62B | |
| -1.20% | -0.36% | +34.42% | +22.90% | 34.34B | |
| -0.89% | +2.25% | +28.92% | +27.68% | 29.46B | |
| +0.22% | -2.71% | +169.96% | +361.83% | 19.11B | |
| -1.01% | +4.38% | +58.47% | +198.43% | 14.78B | |
| +2.31% | -6.43% | +2,918.75% | +3,811.51% | 14.25B | |
| -1.59% | -0.97% | +65.77% | +157.65% | 14.09B | |
| +0.25% | -4.10% | +35.07% | +2.59% | 13.25B | |
| -1.65% | +0.51% | +169.43% | +101.91% | 12.42B | |
| Average | -0.28% | -1.06% | +349.41% | +465.87% | 22.54B | |
| Weighted average by Cap. | -0.14% | -0.73% | +228.83% | +303.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.24B 14.69B 13.59B 12.8B 23.84B 1,604B 24.33B 159B 62.4B 770B 64.71B 63.34B 2,744B | 18.26B 15.55B 14.39B 13.55B 25.24B 1,698B 25.76B 169B 66.07B 815B 68.51B 67.06B 2,905B |
| Net income | 1.45B 1.24B 1.14B 1.08B 2B 135B 2.05B 13.41B 5.25B 64.76B 5.44B 5.33B 231B | 1.69B 1.44B 1.33B 1.25B 2.33B 157B 2.38B 15.59B 6.1B 75.3B 6.33B 6.19B 268B |
| Net Debt | 13B 11.08B 10.25B 9.65B 17.98B 1,209B 18.34B 120B 47.05B 581B 48.79B 47.75B 2,069B | 12.2B 10.4B 9.62B 9.06B 16.87B 1,135B 17.22B 113B 44.16B 545B 45.79B 44.82B 1,942B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/04/26 | 167.34 $ | -0.97% | 1,454,513 |
| 09/04/26 | 168.98 $ | -2.06% | 1,912,651 |
| 08/04/26 | 172.54 $ | +1.13% | 1,756,696 |
| 07/04/26 | 170.62 $ | -0.06% | 1,336,133 |
| 06/04/26 | 170.72 $ | -1.47% | 1,155,344 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IQV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition